NLA 1
| Code | Size | Price |
|---|
| TAR-T33698-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
NLA 1 is a bioreductive compound.
CAS:
140448-36-8
Formula:
C19H18ClN5O2
Molecular Weight:
383.84
Purity:
0.98
SMILES:
Cl.[O-][N+](=O)c1nccn1CCCNc1c2ccccc2nc2ccccc12
References
Denny WA, Roberts PB, Anderson RF, Brown JM, Phil D, Wilson WR. NLA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int J Radiat Oncol Biol Phys. 1992;22(3):553-6. PubMed PMID: 1735695.
Papadopoulou MV, Rosenzweig HS, Doddi M, Bloomer WD. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol Res. 1994;6(9):439-48. PubMed PMID: 7703530.
Papadopoulou MV, Epperly MW, Shields DS, Bloomer WD. Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two new bioreductive compounds. Jpn J Cancer Res. 1992 Apr;83(4):410-4. PubMed PMID: 1506276; PubMed Central PMCID: PMC5918828.
Papadopoulou MV, Mainwaring A, Bloomer WD. Potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea's toxicity in vitro by two new bioreductive agents. Jpn J Cancer Res. 1992 Aug;83(8):907-13. PubMed PMID: 1399828; PubMed Central PMCID: PMC5918954.